Although mitochondrial function is often altered in cancer, it remains essential for tumor viability. Tight control of protein homeostasis is required for the maintenance of mitochondrial function, and the mitochondrial matrix houses several coordinated protein quality control systems. These include three evolutionarily conserved proteases of the AAA þ superfamily-the Lon, ClpXP and m-AAA proteases. In humans, these proteases are proposed to degrade, process and chaperone the assembly of mitochondrial proteins in the matrix and inner membrane involved in oxidative phosphorylation, mitochondrial protein synthesis, mitochondrial network dynamics and nucleoid function. In addition, these proteases are upregulated by a variety of mitochondrial stressors, including oxidative stress, unfolded protein stress and imbalances in respiratory complex assembly. Given that tumor cells must survive and proliferate under dynamic cellular stress conditions, dysregulation of mitochondrial protein quality control systems may provide a selective advantage. The association of mitochondrial matrix AAA þ proteases with cancer and their potential for therapeutic modulation therefore warrant further consideration. Although our current knowledge of the endogenous human substrates of these proteases is limited, we highlight functional insights gained from cultured human cells, protease-deficient mouse models and other eukaryotic model organisms. We also review the consequences of disrupting mitochondrial matrix AAA þ proteases through genetic and pharmacological approaches, along with implications of these studies on the potential of these proteases as anticancer therapeutic targets.
INTRODUCTION
The maintenance of protein homeostasis is critical for cell viability. Proteins must be correctly folded, appropriately assembled into multimeric complexes and degraded when damaged or unneeded. Eukaryotic cells possess several protein quality control systems to refold, reassemble, degrade or sequester proteins, coordinated across distinct cellular compartments. 1 The majority of nuclear, cytoplasmic and endoplasmic reticulum (ER) proteins requiring removal or turnover are ubiquitylated and delivered to the 26S proteasome for degradation, whereas others are cleared through autophagic delivery to lysosomes. [1] [2] [3] [4] In contrast to other cellular compartments and as a legacy of their endosymbiotic heritage, mitochondria maintain independent protein synthesis and degradation machinery. Mitochondria contain over 1000 unique proteins encoded by the nuclear genome (nDNA), in addition to 13 proteins encoded by the small, circular, doublestranded mitochondrial genome (mtDNA) that are synthesized in the mitochondrial matrix using distinct mitochondrial ribosomes and translation machinery. [5] [6] [7] These 13 proteins form subunits of the respiratory chain complexes found in the inner mitochondrial membrane, assembling with 77 nDNA-encoded proteins to form five intact respiratory complexes arranged in an electron transport chain for the aerobic generation of ATP through oxidative phosphorylation ( Figure 1a ). [8] [9] [10] Mitochondria also possess distinct protein quality control and degradation systems. Although dysregulation of the ubiquitinproteasome system in the cytoplasm has been observed in cancer and may be therapeutically modulated with proteasome inhibitors such as the FDA-approved drug bortezomib, 11 the impact of suppressing mitochondrial protein quality control in tumor cells is uncertain. Approximately 20 peptidases have been found throughout the different compartments of human mitochondria (that is, the outer mitochondrial membrane, intermembrane space, inner mitochondrial membrane and mitochondrial matrix), including five major proteases involved in mitochondrial protein degradation. 12, 13 For example, the serine protease HTRA2 (high temperature requirement A serine peptidase 2; also known as OMI) is predominantly found in the mitochondrial intermembrane space.
14 HTRA2 is released from the mitochondria into the cytoplasm upon induction of apoptosis, where it can mediate apoptotic and oncogenic signaling by cleaving substrates such as inhibitor of apoptosis proteins (IAPs) and Wilms tumor suppressor protein 1 (WT1). [14] [15] [16] [17] However, its physiological function in the mitochondria is not fully understood.
proteins in the mitochondrial matrix and inner mitochondrial membrane. This review provides an overview of the three mitochondrial matrix AAA þ proteases and assesses their roles as putative targets for novel anticancer therapeutics. Where possible, known features of the human Lon, ClpXP and m-AAA proteases are highlighted, and additional insights from their homologs in model organisms (Table 1) are summarized.
THE LON PROTEASE
Approximately two decades ago, the first human mitochondrial matrix AAA þ protease was identified based on its similarity to the bacterial Lon (also known as La) protease. 21, 22 Although its function has not yet been fully characterized, the human Lon protease-LONP1 (lon peptidase 1, mitochondrial; alternately denoted as LON or LONM)-appears to maintain mitochondrial matrix protein quality, regulate aerobic respiratory function, remove oxidized proteins and regulate mtDNA nucleoid function.
Structure Human LONP1 contains an N-terminal domain (N-domain) that assists in substrate recognition, an AAA þ ATPase module and a serine protease domain (P-domain) containing a catalytic serinelysine dyad ( Figure 2) . 21, 23 Although the structure of an intact mammalian Lon protease has not yet been reported, crystallized P-domain segments of human LONP1 are hexameric and The mitochondrial matrix contains three proteases of the AAA þ superfamily to modulate protein quality control and degradation. The human Lon protease, LONP1 (lon peptidase 1, mitochondrial), is found in both a free form and in association with mtDNA, which is assembled with several matrix proteins in a complex structure called the nucleoid.
The human ClpXP protease is formed of the CLPP (ClpP caseinolytic peptidase, ATP-dependent, proteolytic subunit homolog (Escherichia coli)) protease in association with the CLPX (ClpX caseinolytic peptidase X homolog (E. coli)) ATPase. The matrix ATPase associated with diverse cellular activity (m-AAA) protease is tethered to the IMM, with its enzymatic domain exposed to the matrix. In humans, this protease can be formed as a heterooligomeric or homooligomeric complex of two subunit types. c, cytochrome c; Clp, caseinolytic peptidase; Q, coenzyme Q. recombinant full-length LONP1 subunits assemble into hexamers in solution. 24 Insights may be gained from the solved structure of the complete Lon protease in the archaeon Thermococcus onnurineus, which also assembles as a hexamer. 25 This crystal structure suggests that the P-domains of each subunit form a bowl-like chamber with a lid formed by the AAA þ domains, such that substrates and degradation products may enter and exit the proteolytic chamber via opposing axial pores. 25 In contrast, the homologous Lon protease in the yeast Saccharomyces cerevisiaePim1p (proteolysis in mitochondria)-was found to form a heptameric ring by cryoelectron microscopy, demonstrating structural diversity between species. 26 
Function
The function of the Lon protease has been extensively studied in S. cerevisiae as a model eukaryote. To date, the substrates of human LONP1 have not been systematically characterized and specific sequence or structural features mediating recognition by this protease remain uncertain. However, several putative human LONP1 substrates have been identified through their accumulation or stabilization in the mitochondria of cultured human cells upon LONP1 perturbation (Table 2 ). Mitochondrial matrix AAA þ proteases are generally thought to degrade proteins in an unfolded state, but recombinant LONP1 can also degrade small folded proteins in vitro, such as unassembled yeast MPPa (mitochondrial processing peptidase, alpha subunit), or murine steroidogenic acute regulatory protein (StAR). 27, 28 The ability to degrade both unfolded and small folded proteins may therefore reflect a broad pool of endogenous LONP1 substrates. The degradation of several of these putative substrates is directly linked to the maintenance of essential mitochondrial functions, as discussed below.
Maintenance of aerobic respiration. To maintain aerobic respiration, mitochondria must coordinate a stoichiometric balance between nDNA-encoded and mtDNA-encoded respiratory complex subunits, ensure assembly of intact complexes, and degrade excess unassembled subunits. Studies in S. cerevisiae first demonstrated that the Lon protease contributes to fulfilling this function. 29, 30 Yeast deficient in Pim1p expression display a remarkable respiratory defect associated with abnormal mitochondrial morphology and an accumulation of electron-dense inclusions in the matrix. 30 These inclusions probably represent aggregates of Pim1p substrates, which include several mitochondrial metabolic enzymes and respiratory complex subunits, required for the citric acid cycle and oxidative phosphorylation, respectively. [30] [31] [32] [33] [34] Independent of its proteolytic activity, Pim1p may also chaperone the assembly of multimeric inner mitochondrial membrane protein complexes, including respiratory complexes IV and V. 35, 36 Complementation studies replacing Pim1p with murine Lon suggest that at least some of these functions are likely to be conserved in mammals. 37 In support of this notion, the human Lon protease appears to chaperone the assembly of complex IV under several stress conditions. 38 Response to cellular and environmental stress. Several studies in both yeast and mammals indicate that expression of the Lon protease is induced in response to cellular or environmental stress. For example, in yeast, Pim1p is upregulated by oxidative stress (that is, a cellular stress) and by heat stress (that is, an environmental stress). 29, 33 Likewise, in mammalian systems, the Lon protease is upregulated by oxidative and heat stress, as well as serum starvation, ER stress and hypoxia. [38] [39] [40] [41] [42] Mitochondria must cope with being uniquely exposed to high levels of oxidative stress because of the production of reactive oxygen species as a byproduct of oxidative phosphorylation, and these reactive oxygen species can modify and inactivate nearby mitochondrial matrix proteins. 43 In response to mitochondrial oxidative stress, the Lon protease appears to have an important role in the degradation of oxidized proteins. For example, in yeast, Pim1p is instrumental in the degradation of proteins sensitive to damage by reactive oxygen species and prone to aggregation. [32] [33] [34] Similarly, in mammalian systems, suppression or inactivation of the Lon protease is associated with an accumulation of oxidized proteins. 42, [44] [45] [46] [47] [48] The first substrate of the mammalian Lon protease to be identified, ACO2, (aconitase 2, mitochondrial), is an iron/sulfur cluster protein integral to the citric acid cycle whose function is susceptible to oxidative damage. 48 This report found that mildly oxidized ACO2 purified from porcine heart muscle was selectively degraded by LONP1 purified from bovine heart muscle. Complementary studies demonstrated that suppression of human LONP1 expression in transformed embryonic lung fibroblasts led to an accumulation of oxidized ACO2. 48 However, a ceiling for effective Lon protease-mediated protective degradation appears to exist. For instance, severe oxidation of ACO2 leads to its aggregation and escape from degradation by the Lon protease. 48 Furthermore, the Lon protease is itself susceptible to inactivation by oxidative damage. 49, 50 Along with maintaining protein homeostasis upon oxidative stress, LONP1 enables the mitochondria to fine tune oxidative phosphorylation efficiency in response to the environmental availability of oxygen. In human tumor cell lines, hypoxic conditions trigger a switch in isoform expression of the complex IV subunit cytochrome c oxidase subunit IV (COX4) from COX4I1 (isoform 1) to COX4I2 (isoform 2). 40 The rapid decrease in COX4I1 protein levels under hypoxia has been attributed to degradation of this protein by LONP1. 40 Regulation of mitochondrial DNA nucleoid function. In addition to defending the mitochondria from the accumulation of oxidized protein and modulating respiratory function, the Lon protease has a role in regulating mtDNA and nucleoid function. A subpopulation of LONP1 can be found in mtDNA nucleoids, and LONP1 interacts with several nucleoid-associated proteins. [51] [52] [53] Through mechanisms related to regulating the rapid degradation of TFAM (transcription factor A, mitochondrial), a mitochondrial transcription factor and major nucleoid constituent, human LONP1 may influence the abundance and accessibility of mtDNA. 50, 54 In addition, LONP1 can bind directly to mtDNA, although the effects of this binding are not yet clear. 50, 51, 55 Association of the Lon protease with cellular transformation and cancer Several studies have linked the Lon protease to cellular transformation. For instance, murine Lon expression was induced concurrently with the epidermal growth factor-mediated transformation of an epidermal cell line. 56 This induction was dependent on mitogen-activated protein kinase kinase 1 (MAP2K1, also known as MEK1) and phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) signaling, 56 placing Lon downstream of two pathways commonly deregulated in cancer. 57 Lon upregulation was also observed in mitochondria isolated from rat hepatomas. 58 In the context of human cancer, elevated LONP1 expression has been observed in a mammary epithelial cell line overexpressing the proto-oncogene v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 (ERBB2, also known as HER2), 56 non-small-cell lung cancer cell lines compared with fetal or embryonic lung fibroblasts, 59 and lymphoma cell lines and primary samples compared with normal peripheral B cells. 60 Thus, increased Lon protease expression and activity has been associated with transformation. However, the induction of Lon expression by oncogenic signaling suggests that upregulation of the Lon protease is a consequence of transformation rather than a causative factor.
The Lon protease as an anticancer target Given the critical role of the Lon protease in maintaining mitochondrial function, it has been explored in preclinical studies as a potential therapeutic target in cancer. To begin, several studies have investigated the consequences of LONP1 knockdown in cultured human cell lines. The cytotoxic effects of LONP1 disruption have thus far been cell line dependent. LONP1 knockdown in transformed human embryonic lung fibroblasts triggered robust caspase-3-dependent cell death, severe mitochondrial dysfunction and reduced proliferation in surviving cells, and accumulation of electron-dense aggregates in the mitochondrial matrix. 61 A subpopulation of surviving cells emerged characterized by reduced mtDNA content, an observation that has also been noted in senescent fibroblasts with low LONP1 expression. 42, 61 LONP1 knockdown also reduced viability in human cell lines derived from mantle cell lymphoma and non-small-cell lung cancer. 59, 60 In contrast, other transformed human cell lines have been shown to tolerate LONP1 knockdown for several days or weeks, although disruptions of mitochondrial function and alterations in cellular signaling were sometimes detected. 50, 54, 60, 62, 63 The mechanisms underlying differential sensitivity to LONP1 suppression are likely to be multifactorial, but may reflect differences in residual LONP1 expression, dependence on its function, and compensatory mechanisms.
Pharmacological inhibition of LONP1 has also been evaluated as a preclinical anticancer therapeutic strategy. For example, inhibition of LONP1 by the natural compound obtusilactone A or the synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (also known as CDDO) induced cell death in non-small-cell lung carcinoma and lymphoma cell lines, respectively. 59, 60 However, these small molecules have additional mechanisms of action, and thus the contribution of Lon protease inhibition to their cytotoxicity is unclear. Overall, the Lon protease has been found to be upregulated in cancer, perhaps as a result of upstream oncogenic signaling, increased mitochondrial biogenesis, and increased mitochondrial stress. Although the effect of perturbing LONP1 differs between transformed cell lines, identifying characteristics of tumor cells particularly responsive to LONP1 inhibition may identify promising therapeutic opportunities. The potential therapeutic window of LONP1 inhibition is not yet clear, and characterization of LONP1-deficient animal models would help in this regard. In addition, the continued development and characterization of LONP1-specific inhibitors and activity reporters should facilitate further evaluation of the potential of LONP1 as an anticancer target. 64, 65 THE CLPXP PROTEASE In contrast to the Lon protease, the ClpXP complex is one of the least characterized mitochondrial proteases in humans. In part, the lack of knowledge of ClpXP protease function stems from the absence of a homologous protease in the yeasts S. cerevisiae or S. pombe. 66 The human ClpXP protease is a complex formed of two proteins-the proteolytic CLPP (ClpP caseinolytic peptidase, ATP-dependent, proteolytic subunit homolog (E. coli)) and an ATPase chaperone, CLPX (ClpX caseinolytic peptidase X homolog (E. coli)). [67] [68] [69] Although the precise function of the human ClpXP protease remains elusive, it is predicted to be involved in protein quality control and mitochondrial stress response signaling by its similarity to homologs in model organisms.
Structure CLPP contains a serine protease domain with a classic catalytic triad, whereas CLPX contains an AAA þ ATPase domain (Figure 2) . [68] [69] [70] CLPP is stable as a heptameric ring, but lacks processive proteolytic activity in the absence of interaction with CLPX. 67, 69, [71] [72] [73] Transient face-to-face interactions between two CLPP heptamers are stabilized in the presence of ATP by capping either end of the resulting tetradecamer with hexameric CLPX rings, which allosterically trigger a conformational change in CLPP active sites. 67, 71, 72, 74 This forms an inner aqueous chamber where substrates can be degraded, similar to the barrel of the cytoplasmic 26S proteasome. 71, 72, 75, 76 Substrate recognition is mediated by CLPX, although specific recognition features remain unknown. 67, 74 The unfolding of substrates has been proposed to stimulate the ATPase activity of CLPX, loosening interactions between neighboring CLPP subunits to coordinate release of processed peptides. 71 Putative functions Protein quality control. Although recombinant human ClpXP degrades model peptides and proteins such as casein, specific endogenous substrates have not yet been identified. 64, 67, 71, 72, 74 However, insights may be gained from the function of the homologous protease in bacteria, as the amino-acid sequences of human CLPP and CLPX are 56 and 44% identical to their counterparts in E. coli, respectively. 67 High-throughput studies in bacteria have identified over 100 proteins as substrates of the bacterial ClpXP protease, with an enrichment for cell stress response proteins. [77] [78] [79] In bacteria, ClpX recognizes substrates modified with a small stable RNA (ssrA) protein tag added during stalled protein synthesis, or those that possess five classes of short amino-acid degradation tags, or degrons. 78, 80 Structural differences between ClpX in E.coli and human CLPX mediate species-dependent differences in substrate specificities, 67 and recognition motifs for the human ClpXP protease are unknown. Further functional characterization of the human ClpXP protease is therefore required. 83 the UPR mt couples retrograde communication of unfolded protein stress in the mitochondria to changes in expression of nDNA-encoded regulators of mitochondrial protein homeostasis such as the ClpP homologs and mitochondrial chaperones of the heat-shock protein 60 kDa (HSP60) and heat shock protein 70 kDa (HSP70) families. [84] [85] [86] [87] This response can be induced by the disruption of mitochondrial matrix protease or chaperone function, accumulation of unassembled respiratory complex subunits or ectopic overexpression of a matrix-targeted protein prone to misfolding. [85] [86] [87] [88] [89] [90] Based on these studies, it is hypothesized that peptides produced by ClpXP protease activity are transported out of the mitochondria to trigger the UPR mt transcriptional response in the nucleus. Recently, the ATP-binding cassette transporter HAF-1 (half transporter (P-glycoprotein related)) has been identified in C. elegans as a mediator of mitochondrial efflux of ClpXP protease-cleaved peptides upon mitochondrial stress. 88 Together, these experimental systems have generated the hypothesis that the human ClpXP protease may also have a key role in orchestrating a UPR mt . Whether human homologs of UPR mt players participate in a similar pathway, whether these interactions occur in response to endogenous mitochondrial stress in mammalian cells and their relevance in vivo are questions requiring further investigation.
Emerging role of the ClpXP protease as an anticancer target Few reports have examined the association of the ClpXP protease with disease, although its involvement in UPR mt signaling may be linked to intestinal inflammation. 84 Our understanding of the role of the ClpXP protease in cancer is in its infancy and associations observed thus far appear to be tumor type or context dependent. For example, lower CLPP expression has been detected in gastric adenocarcinomas compared with adjacent resected normal tissue. 91 In contrast, we have recently observed higher expression of CLPP in AML cells compared with normal hematopoietic cells. 92 Clarifying the role of the ClpXP protease in different tumor contexts may therefore provide interesting avenues for future research.
Several inhibitors of bacterial ClpP based on a b-lactone structure have been developed, which demonstrate antimicrobial activity. [93] [94] [95] In addition, constitutive activation of ClpP in bacteria also produces cytotoxic effects. For example, acyldepsipeptide antibiotics bind ClpP and widen the axial channel of the complex, allowing dysregulated cleavage of folded proteins in the absence of the ClpX chaperone. [96] [97] [98] These compounds are consequently bactericidial. Further evaluation of the ability of these approaches to target the human ClpXP protease in transformed cells may clarify the potential of this protease as a therapeutic target in cancer.
THE m-AAA PROTEASE The human m-AAA protease can be formed from two protein subunits: either homooligomers of AFG3L2 (AFG3 ATPase family gene 3-like 2 (S. cerevisiae)) or heterooligomers of AFG3L2 and SPG7 (spastic paraplegia 7 (pure and complicated autosomal recessive), also known as paraplegin). [99] [100] [101] [102] Like LONP1, the human m-AAA protease has a role in the maintenance of aerobic respiration by regulating mitochondrial protein quality and degradation. In addition, the m-AAA protease appears to regulate mitochondrial protein synthesis and network integrity by proteolytically processing key substrates.
Structure
The m-AAA protease is tethered to the inner mitochondrial membrane. Each m-AAA subunit contains two N-terminal transmembrane domains, an AAA þ ATPase module consistent with the classic AAA clade and a metalloprotease domain (Figure 2) . 103 Structural studies of the human SPG7 AAA domain and full-length m-AAA protease subunits in S. cerevisiae suggest that eukaryotic m-AAA subunits form hexameric rings in the inner mitochondrial membrane, with their enzymatic domains exposed to the matrix and proteolytic active sites facing an inner chamber. 103, 105 The spatial orientation of the holoenzyme suggests that it primarily accommodates unfolded protein substrates, consistent with its minimal 'unfoldase' activity. 104, 106 The AAA þ domain may therefore feed unfolded substrates through a central pore to the underlying proteolytic chamber and degraded peptides are likely to be released through lateral exit pores. 104 
Function
Maintenance of aerobic respiration. The m-AAA protease helps to maintain aerobic respiratory function via its role in protein quality control and degradation. Similar to Pim1p-deficient yeast, yeast deficient for the m-AAA protease have a robust respiratory defect and decreased ATP synthesis. [107] [108] [109] [110] [111] [112] [113] These defects have been attributed to suppressed degradation of incompletely synthesized, unassembled respiratory chain complexes in the inner mitochondrial membrane, 108, 113 disrupted assembly of complexes III, IV and V, [109] [110] [111] [112] and interference with mRNA splicing of the complex IV subunit cytochrome c oxidase (Cox1) and the complex III subunit cytochrome b (Cob). 112 Although substrates of mammalian m-AAA proteases remain largely unknown, both human and murine m-AAA proteases can functionally replace the homologous protease complex in yeast, demonstrating some degree of functional conservation. 101, 102, [114] [115] [116] Indeed, in human cells where respiratory complexes are destabilized through truncation of key subunits or knockdown of assembly factors, expression of the human m-AAA protease subunit AFG3L2 is upregulated and appears to degrade several subunits of complexes I and IV. 117, 118 The human Cox1 homolog, mitochondrially encoded cytochrome c oxidase I (MT-CO1), was also shown to coimmunoprecipitate with a proteolytically inactive AFG3L2 variant, providing further support for this complex IV subunit as a putative substrate. 117 Notably, interfering with AFG3L2 activity under conditions of unassembled respiratory complex stress was preferentially cytotoxic compared with conditions where respiratory complexes formed normally, 117 implying that inhibition of the m-AAA protease may be selectively toxic to cells with high levels of mitochondrial stress.
Regulation of mitochondrial protein synthesis. In addition to degrading respiratory complex proteins and chaperoning their assembly, the m-AAA protease also appears to regulate the proteolytic processing of several substrates. For example, in yeast, the m-AAA protease (i) actively dislocates cytochrome c peroxidase (Ccp1p) through the inner mitochondrial membrane using the power of coordinated ATP hydrolysis, (ii) participates in an initial processing step, and (iii) places the substrate in the proper orientation for intramembrane cleavage and maturation by the rhomboid protease Pcp1p (processing of cytochrome c peroxidase). 114, 119, 120 In addition, the yeast m-AAA protease initiates N-terminal degradation of the soluble mitochondrial large ribosome subunit mitochondrial ribosomal protein L32 (MrpL32), but this is terminated proximal to a tightly folded domain, protecting this substrate from complete degradation and releasing mature MrpL32. 121 Aberrant processing of MrpL32 in m-AAA protease-deficient yeast interferes with mitochondrial protein synthesis, making a major contribution to the respiratory incompetence observed in these cells. 115 The ability to process MrpL32 is conserved in the murine m-AAA protease, suggesting that the importance of this substrate may extend to higher mammalian eukaryotes. 115 In the context of human cells, sustained knockdown of AFG3L2 in immortalized skin fibroblasts suppressed mitochondrial protein synthesis and decreased respiratory complex levels, although the processing status of MRPL32 was not examined. 118 Regulation of mitochondrial network dynamics. Proteolytic processing by the m-AAA protease has also been implicated in the regulation of mitochondrial network dynamics in transformed human cell lines. AFG3L2 knockdown increased accumulation of an intermediate processing product of the mitophagy-associated protein phosphatase and tensin homolog induced putative kinase 1 (PINK1), triggering a sublethal increase in mitochondrial fragmentation. 122 In addition, the m-AAA protease may participate in the proteolytic regulation of OPA1 (optic atrophy 1 (autosomal dominant)), a key GTPase involved in mitochondrial fusion. 119, 123, 124 However, the interplay between these proteins is complex. For instance, disrupting m-AAA protease function with a dominant negative AFG3L2 variant unexpectedly increased OPA1 processing through the action of another mitochondrial inner membrane peptidase, OMA1 (OMA1 zinc metallopeptidase homolog (S. cerevisiae)), which is triggered by mitochondrial dysfunction and stress. 119 In this context, m-AAA protease perturbation resulted in a significant degree of mitochondrial fragmentation associated with reduced cellular proliferation. 119 Evidence to date therefore supports a conserved role of the human m-AAA protease in the maintenance of mitochondrial function, although details of the specific substrates and processes affected are limited. Identifying additional human m-AAA protease substrates and validating their biological relevance remain valuable ongoing efforts.
Consequences of disrupting the m-AAA protease in vivo Disruption of m-AAA protease function in vivo places the functional insights gleaned from model organisms and cultured human cells into a physiological context. Loss-of-function mutations in either AFG3L2 or SPG7 lead to a number of distinctive human neuropathies characterized by ataxia and paraplegia. 100, [125] [126] [127] The molecular underpinnings of these neurological phenotypes appear in part to involve mitochondrial dysfunction. For example, human fibroblasts isolated from SPG7-deficient hereditary spastic paraplegia patients demonstrate reduced complex I activity because of defects in complex assembly. 101 Genetic studies in mice have modeled the involvement of Spg7 or Afg3l2 deficiency in neuropathy, also revealing defects in mitochondrial respiratory function and network dynamics. [128] [129] [130] [131] [132] [133] Constitutive Spg7 À / À knockout mice displayed late-onset degeneration of long neuronal axons, preceded by progressive motor impairment. 133 This was accompanied by abnormal mitochondrial morphology in the distal portion of long axons and in the synaptic terminals of the spinal cord, and modest respiratory defects in mitochondria from the spinal cord. 133 In addition, an accumulation of immature MrpL32 has been detected in mitochondria from the liver-but not brain-of Spg7 À / À mice, accompanied by decreased mitochondrial protein synthesis. 115 Constitutive Afg3l2-deficient mice developed severe neuromuscular symptoms with an earlier onset, progressing to paralysis and death by approximately 2 weeks of age. 128 In this case, loss of Afg3l2 was associated with a defect in large axonal development, rather than degeneration. 128 These mice also displayed abnormal mitochondrial morphology and significant suppression of complex I assembly and activity in mitochondria from the brain or spinal cord. 128 Moreover, mitochondrial protein synthesis has recently been reported to be defective in mitochondria from the brain and liver of Afg3l2 null mice, accompanied by impaired mitochondrial ribosome assembly. 131 However, this was not observed in the initial characterization of the Afg3l2 null model, and reasons for this discrepancy are not clear. 128 In both Spg7-and Afg3l2-deficient mouse models, pathology was mostly restricted to the neurons of the central and peripheral nervous systems, with only minor involvement of other tissues, such as skeletal muscle. 128, 133 Emerging role of the m-AAA protease as an anticancer target Taken together, functional studies of the m-AAA protease suggest that inhibition of this protease in humans may lead to severe dysregulation of mitochondrial function. The m-AAA protease may therefore be positioned as a novel therapeutic target in malignancies recently reported to be dependent on mitochondrial function for survival, such as acute myeloid leukemias or a subset of melanomas. [134] [135] [136] [137] To our knowledge, pharmacological inhibitors of the m-AAA protease are not currently available, and the development of such tools will facilitate probing both the biological function of this protease and its potential as a therapeutic target in cancer. Given that the consequences of m-AAA protease deficiency are generally confined to the nervous system in mouse models, the key to developing a lead therapeutic for use in vivo may be ensuring that the compound cannot penetrate the blood-brain barrier.
PERSPECTIVES
Our understanding of the physiological roles of human mitochondrial matrix AAA þ proteases is still evolving, and with greater knowledge of their biology we will be better equipped to assess their potential as novel therapeutic targets in malignancy. Disruption of the expression and activity of these proteases modulates several mitochondrial processes dysregulated in cancer, and has identified a small number of putative human substrates that accumulate in the matrix (Figure 3) . Confidence in the status of a mitochondrial matrix protein as a true, direct substrate would be strengthened through demonstration of a physical interaction with its proposed protease in intact mitochondria, its degradation by the purified protease in vitro, and ideally its accumulation in vivo in protease-deficient mammalian models. The systematic identification of candidate human m-AAA, ClpXP and LONP1 protease substrates, accompanied by comprehensive validation, would mark a major advance in our understanding of mitochondrial protein quality control in health and disease.
Probing the biological function of mitochondrial matrix AAA þ proteases would be facilitated by the development of potent, specific inhibitors of each protease. Once imported into the mitochondria and processed to their mature form, these proteases can be very stable and thus may be more responsive to pharmacological inhibition than genetic knockdown. 22, 37 Although many functional studies of matrix AAA þ proteases have employed pharmacological inhibitors as tools, their specificity among proteases and cellular compartments must be fully characterized to permit complete interpretation of results in intact cells. In parallel with specific inhibitor development, the development of companion activity probes to detect specific proteolysis would be beneficial. Specificity of activity probes has been a difficult issue to address given the broad range of AAA þ protease substrates and lack of known recognition features. This may be aided by the high-throughput identification of candidate substrates for each protease, where common sequence or structural features may emerge.
Thus far, it appears that interfering with human mitochondrial matrix AAA þ proteases induces cytotoxic responses in some, but not all, cell types or cell lines. Currently, whether cytotoxicity induced by disruption of these proteases is the result of deregulating a specific substrate or function, or as a result of a more global disturbance of mitochondrial stress homeostasis is also unknown. As the association of matrix AAA þ proteases with cancer becomes clearer, further insight into the causes of differential sensitivity to protease inhibition may materialize. When evaluating the potential of these proteases as targets for anticancer therapeutic modulation, one must also consider the potential therapeutic window. It is plausible that the additional stresses encountered by tumor cells would make them selectively sensitive to disruption of mitochondrial protein quality control. Notably, other stress-induced proteins such as chaperones of the HSP70 and HSP90 family have been targeted with promising preclinical benefit and therapeutic index in cancer. 138, 139 A more complete appreciation of differential tissue distribution of each of the three matrix AAA þ proteases and tissue-specific sensitivity to their inhibition in vivo will be instrumental in assessing the value of these proteases as anticancer targets and potential adverse toxicities to be expected upon their inhibition.
ClpXP
In the 20 years since the initial characterization of LONP1, many functional insights have been gleaned from eukaryotic model systems and cultured human cells. Adding to this foundation of knowledge and addressing outstanding questions regarding the role of mitochondrial proteases in cancer provide a wealth of interesting research avenues for years to come.
